The white and the three-letter plague: Integration of TB and HIV care in sub-Saharan Africa

Future HIV Therapy

Volumn 2, Issue 5, 2008, Pages 437-451

  Wallrauch, Claudia ^a   Bärnighausen, Till ^a,b   Heller, Tom ^c   Houlihan, Catherine ^a   Newell, Marie Louise ^a,d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Hlabisa Hospital   (South Africa)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Africa; Conaboration; HIV infection; Integration; PITC; Resource limited setting; Tuberculosis; Voluntary testing and counseling

Indexed keywords

AMIKACIN; ANTIRETROVIRUS AGENT; BCG VACCINE; CAPREOMYCIN; COTRIMOXAZOLE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ANEMIA; CLINICAL TRIAL; EPIDEMIC; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LUNG TUBERCULOSIS; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PATIENT COUNSELING; PREVALENCE; REVIEW; SHORT COURSE THERAPY; SUPPORT GROUP; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 55349107784     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.5.437     Document Type: Review

References (121)

1. Steinberg J: Three Letter Plague.' A Young Man's Journey Through a Great Epidemic. Jonathan Ball Publishers, Johannesburg, Gauteng, South Africa (2008).
2. Porter R: The Cambridge History of Medicine. Cambridge University Press, Cambridge, UK (2006).
3. Allen S, Batungwanayo J, Kerlikowske K et al.: Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am. Rev. Respir. Dis. 146(6),1439-1444 (1992).
4. Selwyn PA, Hartel D, Lewis VA et al.: A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J Med. 320(9), 545-550 (1989).
5. Di Perri C, Cruciani M, Danzi MC et al.: Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 2(8678-8679), 1502-1504 (1989).
6. Daley CL, Small PM, Schecter GF et al.: An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N. Engl. J. Med. 326(4), 231-235 (1992).
7. Wood R, Maartens G, Lombard CJ: Risk factors for developing tuberculosis In HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J. Acquir. Immune Defic. Syndr. 23(1), 75-80 (2000).
8. Booysen Fie R, Summerton J: Poverty, risky sexual behaviour, and vulnerability to HIV infection: evidence from South Africa. J. Health Popul. Nutri. 20(4), 285-288 (2002).
9. Buve A, Bishikwabo-Nsarhaza K, Mutangadura G: The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 359(9322), 2011-2017 (2002).
10. Davies PD: The world-wide increase in tuberculosis: how demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann. Med. 35(4), 235-243 (2003).
11. Bärnighausen T: Access to antiretroviral treatment in the developing world:
12. a framework, review and health systems research agenda. Theraphy 4(6), 753-766 (2007).
13. Suarez PG, Watt CJ, Alarcon E et al.: The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J. Infect. Dis. 184(4), 473-478 (2001).
14. Dye C, Fengzeng Z, Scheele S, Williams B: Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int. J. Epidemiol. 29(3), 558-564 (2000).
15. Maartens G, Wilkinson RJ: Tuberculosis. Lancet 370(9604), 2030-2043 (2007).
16. Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW: HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10(6), 663-669 (2006).
17. Jahn A, Floyd S, Crampin AC et al.: Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371 (9624), 1603-1611 (2008).
18. Lawn SD, Myer L, Bekker LG, Wood R: Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21 (3), 335-341 (2007).
19. Kwara A, Flanigan TP, Carter EJ: Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int. J. Tuberc. Lung Dis. 9(3), 248-257 (2005).
20. WHO: Interim Policy On Collaborative TB/HIV Activities. WHO, Geneva, Switzerland (2004).
21. WHO: The Global Plan To Stop TB 2006-2015. WHO, Geneva, Switzerland (2006).
22. Tsiouris SJ, Gandhi NR, El-Sadr WM, Friedland G: Tuberculosis and HIV needed: a new paradigm for the control and management of linked epidemics. MedGenMed. 9(3), 62 (2007).
23. Nachega J, Coetzee J, Adendorff T et al.: Tuberculosis active case-finding in a mother-to-child HIV transmission prevention programme in Soweto, South Africa. AIDS 17(9), 1398-1400 (2003).
24. De Cock KM, Chaisson RE: Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int. J. Tuberc. Lung. Dis. 3(6), 457-465 (1999).
25. Harries AD, Maher D, Nunn P: Practical and affordable measures for the protection of health care workers from tuberculosis In low-income countries. Bull. World Health Organ. 75(5), 477-489 (1997).
26. Matee M, Mtei L, Lounasvaara T et al.: Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health 8, 68 (2008).
27. Urbanczik R: Present posisition of microscopy and of culture in diagnostic mycobacteriology. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A]260(1), 81-87 (1985).
28. Behr MA, Warren SA, Salamon H et al.: Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353(9151), 444-449 (1999).
29. Hawken MP, Muhindi DW, Chakaya JM, Bhatt SM, Ng'ang'a LW, Porter JD: Under-diagnosis of smear-positive pulmonary tuberculosis in Nairobi, Kenya.Int. J. Tuberc. Lung Dis. 5(4), 360-363 (2001).
30. Mesfin MM, Tasew TW, Richard MJ: The quality of tuberculosis diagnosis in districts of Tigray region of northern Ethiopia. Ethiop. J. Health Dev. 19, 13-20 (2005).
31. Bennedsen J, Larsen SO: Examination for tubercle bacilli by fluorescence microscopy. Scand. J. Respir. Dis. 47(2), 114-120 (1966).
32. Steingart KR, Henry M, Ng V et al.: Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect. Dis. 6(9), 570-581 (2006).
33. Marais BJ, Brittle W, Painczyk K et al.: Use of light-emitting diode fluorescence microscopy detect acid-fast bacilli in sputum. Clin. Infect. Dis. 47, 203-207 (2008).
34. van Cleeff MR, Kivihya-Ndugga LE, Meme H, Odhiambo JA, Klatser PR: The role and performance of chest x-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect. Dis. 5, 111 (2005).
35. Keiper MD, Beumont M, Elshami A, Langlotz CP, Miller WT Jr: CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. A study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 107(1), 74-80 (1995).
36. Bakari M, Arbeit RD, Mtei Let al. Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect. Dis. 8, 32 (2008).
37. WHO: Improving the Diagnosis and Treatment Of Smear-negative Pulmonary and Extrapulmonary Tuberculosis Among Adults and Adolescents. WHO, Geneva, Switzerland (2007).
38. Wilkinson D, Newman W, Reid A, Squire SB, Sturm AW, Gilks CF: Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. Int. J. Tuberc. Lung Dis. 4(6), 513-518 (2000).
39. WHO: Antiretroviral Therapy For HIV Infection In Adults And Adolescents Volume (Revision). WHO, Geneva, Switzerland (2006).
40. Wilson D, Nachega J, Morroni C, Chaisson R, Maartens G: Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. Int. J. Tuberc. Lung Dis. 10(1), 31-38 (2006).
41. Raviglione MC, Smith IM: XDR tuberculosis: implications for global public health. N. Engl. J. Med. 356(7), 656-659 (2007).
42. WHO I: Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO, Geneva, Switzerland (2008).
43. Gandhi NR, Moll A, Sturm AW et al.: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547), 1575-1580 (2006).
44. Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl. Tuberc. 26, 28-106 (1970).
45. Wilkenson D, Squire SB, Garner P: Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 351, 625-629 (1998).
46. Zar HJ, Cotton MF. Strauss S et al.: Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 334(7585), 136 (2007).
47. Bell JC, Rose DN, Sacks HS: Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa Is cost-effective. AIDS 13(12), 1549-1556 (1999).
48. Shrestha RK. Mugisha B, Bunnell R et al.: Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int. J. Tuberc. Lung Dis. 11 (7), 747-754 (2007).
49. LoBue PA, Moser KS: Use of isoniazid for latent tuberculosis infection in a public health clinic. Am. J. Respir. Crit. Care Med. 168(4), 443-447 (2003).
50. UNAIDS/WHO P: Policy statement on preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol. Rec. 74, 385-400 (1999).
51. Szakacs TA, Wilson D, Cameron DW et al.: Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect. Dis. 6, 97 (2006).
52. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM: Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int. J. Tuberc. Lung Dis. 9(3), 263-269 (2005).
53. Churchyard GJ, Scano F, Grant AD, Chaisson ICE: Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J. Infect. Dis. 196(Suppl. 1), S52-S62 (2007).
54. Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G: Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease, Int. J. Tuberc. Lung Dis. 11(10), 1114-1120 (2007).
55. Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW: Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin. Infect. Dis. 43, 634-639 (2006).
56. Menzies R: Tuberculin skin testing. In: Tuberculosis: an International Approach(2nd Edition). Reichman LB, Hershield ES (Eds). Marcel Dekker, NY, USA (2000).
57. Pai M, Riley LW, Colford JM Jr: Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4, 761-776 (2004).
58. Rangaka MX, Wilkinson KA, Seldon R et al.: Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosIs infection. Am. J. Respir. Crit. Care Med. 175(5), 514-520 (2007).
59. Sneag DB, Schaaf HS, Cotton MF, Zar HJ: Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr. Infect. Dis. J. 26(12), 1142-1146 (2007).
60. Fraser A, Paul M, Attamna A, Leibovici L: Treatment of latent tuberculosis in person at risk for multidrug-resistant tuberculosis: systematic review. Int. J. Tuberc. Lung Dis. 10(1), 19-23 (2006).
61. Cohen T, Lipsitch M, Walensky RP, Murray M: Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc. Natl Acad. Sci. USA 103(18), 7042-7047 (2006).
62. WHO: Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings. WHO, Geneva, Switzerland (1999).
63. Joshi R RA, Menzies D, Pai M: Tuberculosis among health care workers in low- and middle-income countries PLoS Med. 3, 2376-2391 (2006).
64. Bock NN, Jensen PA, Miller B, Nardell E: Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J. Infect. Dis. 196(Suppl. 1), S108-S113 (2007).
65. Sidley P: South African health services must strengthen infection control measures. BMJ 328, 366 (2004).
66. Basu S, Andrews JR, Poolman EM et al.: Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370(9597), 1500-1507 (2007).
67. WHO/UNAIDS/UNICEF: Towards universal access: scaling up priority HIV/ AIDS interventions in the health sector. Progress report. WHO, Geneva, Switzerland, April 2007.
68. Van Rie A, Sabue M, Jarrett N et al.: Counseling and testing TB patients for HIV: evaluation of three implementation models In Kinshasa, Congo. Int. J. Tuberc. Lung Dis. 12(3 Suppl. 1), 73-78 (2008).
69. Corneli A, Jarrett NM, Sabue M et al.: Patient and provider perspectives on implementation models of HIV counseling and testing for patients with TB. Int. J. Tuberc. Lung Dis. 12(3 Suppl. 1), 79-84 (2008).
70. Kirungi WL, Musinguzi J, Madraa E et al.: Trends in antenatal HIV prevalence in urban Uganda associated with uptake of preventive sexual behaviour. Sex. Transm. Infect. 82(Suppl. 1), 36-41 (2006).
71. Foss AM, Hossain M, Vickerman PT, Watts CH: A systematic review of published evidence on intervention impact on condom use in sub-Saharan Africa and Asia. Sex. Transm. Infect. 83(7), 510-516 (2007).
72. Magnussen L, Ehiri JE, Ejere HO, Jolly PE: Interventions to prevent HIV/ AIDS among adolescents In less developed countries: are they effective? Int. J. Adolesc. Med. Health 16(4), 303-323 (2004).
73. Kirby D, Obasi A, Laris BA: The effectiveness of sex education and HIV education intervention in schools in developing countries. World Health Organ. Tech. Rep. Ser. 938, 103-150; discussion 317-141 (2006).
74. Creese A, Floyd K, Alban A, Guinness L: Cost effectiveness of HIV/AIDS interventions in Africa: a systematic review. Lancet 359, 1635-1643 (2002).
75. Pillay T, Khan M, Moodley J et al.: The increasing burden of tuberculosis In pregnant women, newborns and infants under 6 months of age in Durban, KwaZulu-Natal. S. Afr. Med. J. 91(11), 983-987 (2001).
76. Khan M, Pillay T, Moodley JM, Connolly CA: Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS 15 (14), 1857-1863 (2001).
77. Ahmed Y, Mwaba P, Chintu C, Grange JM, Ustianowski A, Zumla A: A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. Int. J Tuberc. Lung Dis. 3(8), 675-680 (1999).
78. Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H: Perinatal tuberculosis and HIV-I: considerations for resource-limited settings. Lancet Infect. Dis. 4(3), 155-165 (2004).
79. Behets FM, Matendo R, Vaz LM et al.: Preventing vertical transmission of HIV in Kinshasa, Democratic Republic of the Congo: a baseline survey of 18 antenatal clinics. Bull. World Health Organ. 84(12), 969-975 (2006).
80. Kali PB, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA: Combining PMTCT with active case finding for tuberculosis. J. Acquir. Immune Defic. Syndr. 42(3), 379-381 (2006).
81. Wiktor SZ, Sassan-Morokro M, Grant AD et al.: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality In HIV-1-infected patients with tuberculosis in Abidjan, Cote. d'Ivoire: a randomised controlled trial. Lancet 353(9163), 1469-1475 (1999).
82. Zachariah R, Spielmann MP, Harries AD, Gomani P, Bakali E: Cotrimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo, Malawi. Int. J. Tuberc. Lung Dis. 6(12), 1046-1050 (2002).
83. Anglaret X, Chene G, Attia A et al.: Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 353(9163), 1463-1468 (1999).
84. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF: Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 19(2), 163-168 (2005).
85. Grimwade K, Swingler GH: Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database Syst. Rev. 3, CD003108 (2003).
86. Van't Hoog AH, Onyango J, Agaya J et al.: Evaluation of TB and HIV services prior to introducing TB-HIV activities in two rural districts in western Kenya. Int. J. Tuberc. Lung Dis. 12(3 Suppl. 1), 32-38 (2008).
87. Watera C, Todd J, Muwonge R et al.: Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/ AIDS clinic in Uganda. J. Acquir. Immune Defic. Syndr. 42(3), 373-378 (2006).
88. Watera C, Todd J, Mutonyi G et al.: Effects of cotrimoxazole on hematologic parameters in HIV-infected adults in a community-based clinic in Entebbe, Uganda. J. Acquir. Immune Defic. Syndr. 46(3), 369-371 (2007).
89. Friedland G, Harries A, Coetzee D: Implementation issues in tuberculosis/ HIV program collaboration and integration: 3 case studies. J. Infect. Dis. 196(Suppl. 1), S114-S123 (2007).
90. Wood R: The case for integrating tuberculosis and HIV treatment services in South Africa. J. Infect. Dis. 196(Suppl. 3), S497-S499 (2007).
91. Jack C, Lalloo U, Karim QA et al.: A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J. Acquir. Immune Defic. Syndr. 36(4), 929-934 (2004).
92. Gasana M, Vandebriel G, Kabanda G et al.: Integrating tuberculosis and HIV care in rural Rwanda. Int. J. Turberc. Lung Dis. 12(3 Suppl. 1), 39-43 (2008).
93. Lawn SD, Myer L, Bekker LG, Wood R: CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect. Dis. 6, 59 (2006).
94. Williams BG, Dye C: Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301(5639), 1535-1537 (2003).
95. Badri M, Wilson D, Wood R: Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359(9323), 2059-2064 (2002).
96. Jerene D, Naess A, Lindtjorn B: Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res. Ther. 3, 10 (2006).
97. Girardi E, Palmieri F, Cingolani A et al.: Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 26(4), 326-331 (2001).
98. Onyebujoh PC, Ribeiro I, Whalen CC: Treatment options for HIV-associated tuberculosis. J. Infect. Dis. 196(Suppl. 1), S35-S45 (2007).
99. McShane H: Co-infection with HIV and TB: double trouble. Int. J. STD AIDS 16(2), 95-100 (2005).
100. Maartens G: Managing HIV and tuberculosis in Sub-Saharan Africa. Presented at: The 9th Conference on Retroviruses and Opportunities Infections. Seattle, WA, USA, 24-28 February 2002.
101. Murdoch DM, Venter WD, Feldman C, Van Rie A: Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 22(5), 601-610 (2008).
102. Chesney M: Adherence to HAART regimens. AIDS Patient Care STDS 17 (4), 169-177 (2003).
103. Ingersoll KS, Cohen J: The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J. Behav. Med. 31(3), 213-224 (2008).
104. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J: Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 4(7), e238 (2007).
105. UNAIDS/WHO: Guidance on Provider-initiated HIV Testing and Counseling in Health Facilities. WHO, Geneva, Switzerland (2007).
106. Abdool Karim SS, Abdool Karim KQ, Friedland G, Lalloo U, El-Sadr WM: Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS 18, 975-979 (2004).
107. Bock NN, Nadol P, Rogers M, Fenley MA, Moore J, Miller B: Provider-initiated HIV testing and counseling in TB clinical settings: tools for program implementation. Int. J. Tuberc. Lung Dis. 12(3 SuppL 1), 69-12 (2008).
108. Odhiambo J, Kizito W, Njoroge A et al.: Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya. Int. J. Tuberc. Lung Dis. 12(3 Suppl. 1), 63-68 (2008).
109. CDC: Provider-initiated HIV testing and counselling of TB patients: Livingstone District, Zambia, September 2004-December 2006. MMWR 57(11), 285-289 (2008).
110. Pope SD, Deluca AN, Kali P et al.: A cluster-randomized trial of provider-initiated (opt-out) HIV counseling and testing of tuberculosis patients in South Africa J. Acquir. Immune Defic. Syndr. 48, 190-195 (2008).
111. Barnard M, Albert H, Coetzee G, O'Brian R, Bosman M: Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177(7), 787-792 (2008).
112. Hillemann D, Rüsch-Gerdes S, Richter E: Application of Genotype® MTBDR assay directly on sputum specimens, Int. J. Tuberc. Lung Dis. 10(9), 1057-1059 (2006).
113. Spigelman MK: New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196(Suppl. 1), S28-S34 (2007).
114. Duncan K, Barry CE 3rd: Prospects for new antitubercular drugs Curr. Opin. Microbiol. 7(5), 460-465 (2004).
115. Sharma K, Chopra P, Singh Y: Recent advances towards identifaction of new drug targets for Mycobacterium tuberculosis Expert Opin. Ther. Targets 8(2), 79-93 (2004).
116. Tornioka H: Prospects of new antimicrobacterial drugs. Infect. Chemother. 6(1), 8-20 (2000).
117. Nuermberger EL, Yoshimatsu T, Tyagi S et al.: Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170(10), 1131-1134 (2004).
118. Alvirez-Freites EJ, Carter JL, Cynamon MH: In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46(4), 1022-1025 (2002).
119. Barry CE 3rd, Boshoff HI, Dowd CS: Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Cus. Pharm. Des. 10(26), 3239-3262 (2004).
120. Andries K, Verhasselt P, Guillemont J et al.: A diarylquinoline drug active on ATP synthase of Mycobacterium tuberculosis. Science 307(5707), 223-227 (2005).
121. Sadoh WE, Oviawe O: The economic burden to families of HIV and HIV/ tuberculosis coinfection in a subsidized HIV treatment program. J. Natl Med. Assoc. 99(6), 627-631 (2001).